Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial
Authors:
- 1 October 2014
- Vol. 32 (45) , 5967-5974
Abstract
No abstract availableKeywords
Funding Information
- European Union's Seventh Framework Programme (261954)
This publication has 29 references indexed in Scilit:
- Key roles of adjuvants in modern vaccinesNature Medicine, 2013
- Modern Subunit Vaccines: Development, Components, and Research OpportunitiesChemMedChem, 2013
- Vaccines for the twenty-first century societyNature Reviews Immunology, 2011
- Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccineVaccine, 2011
- The safety evaluation of adjuvants during vaccine development: The AS04 experienceVaccine, 2011
- Trends in vaccine adjuvantsExpert Review of Vaccines, 2011
- New adjuvants for human vaccinesCurrent Opinion in Immunology, 2010
- Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of theNeisseria meningitidisSerogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with ChitosanInfection and Immunity, 2005
- Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosanVaccine, 2004
- Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin AInfection and Immunity, 2003